JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, A. K.
Journal of the American Podiatric Medical Association Volume 92 Number 5 272-286 2002
Copyright © 2002 American Podiatric Medical Association

Treatment of Dermatophyte Toenail Onychomycosis in the United States

A Pharmacoeconomic Analysis

Aditya K. Gupta, MD, FRCPC*

* Associate Professor, Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook campus) and University of Toronto, Toronto, Ontario, Canada. Mailing address: 490 Wonderland Rd S, Ste 6, London, Ontario, Canada N6K 1L6.

Abstract

This study attempted to determine the cost-effectiveness of therapies for dermatophyte toenail onychomycosis in the United States in 2001. The antimycotic agents evaluated were ciclopirox 8% nail lacquer and the oral agents terbinafine, itraconazole (pulse), itraconazole (continuous), fluconazole, and griseofulvin. A treatment algorithm for the management of onychomycosis was developed, and a meta-analysis was carried out to determine the average mycologic and clinical response rates for the various agents. The cost of the regimen was figured as the sum of the costs of drug acquisition, medical management, and management of adverse effects. The expected cost of management and disease-free days were determined, and a sensitivity analysis was conducted. It was concluded that ciclopirox 8% nail lacquer, which has recently become available in the larger size of 6.6 mL, is a cost-effective agent for the management of toenail onychomycosis. (J Am Podiatr Med Assoc 92(5): 272-286, 2002)




This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
E. M. Warshaw
Evaluating Costs for Onychomycosis Treatments: A Practitioner's Perspective
J Am Podiatr Med Assoc, January 1, 2006; 96(1): 38 - 52.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Podiatric Medical Association.